Literature DB >> 20218881

Differential inhibition of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and TZM-bl cells by endotoxin-mediated chemokine and gamma interferon production.

Anthony R Geonnotti1, Miroslawa Bilska, Xing Yuan, Christina Ochsenbauer, Tara G Edmonds, John C Kappes, Hua-Xin Liao, Barton F Haynes, David C Montefiori.   

Abstract

Bacterial lipopolysaccharide (endotoxin) is a frequent contaminant of biological specimens and is also known to be a potent inducer of beta-chemokines and other soluble factors that inhibit HIV-1 infection in vitro. Though lipopolysaccharide (LPS) has been shown to stimulate the production of soluble HIV-1 inhibitors in cultures of monocyte-derived macrophages, the ability of LPS to induce similar inhibitors in other cell types is poorly characterized. Here we show that LPS exhibits potent anti-HIV activity in phytohemagglutinin-stimulated peripheral blood mononuclear cells (PBMCs) but has no detectable anti-HIV-1 activity in TZM-bl cells. The anti-HIV-1 activity of LPS in PBMCs was strongly associated with the production of beta-chemokines from CD14-positive monocytes. Culture supernatants from LPS-stimulated PBMCs exhibited potent anti-HIV-1 activity when added to TZM-bl cells but, in this case, the antiviral activity appeared to be related to IFN-gamma rather than to beta-chemokines. These observations indicate that LPS stimulates PBMCs to produce a complex array of soluble HIV-1 inhibitors, including beta-chemokines and IFN-gamma, that differentially inhibit HIV-1 depending on the target cell type. The results also highlight the need to use endotoxin-free specimens to avoid artifacts when assessing HIV-1-specific neutralizing antibodies in PBMC-based assays.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20218881      PMCID: PMC2864054          DOI: 10.1089/aid.2009.0186

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  85 in total

1.  Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.

Authors:  John R Mascola; Patricia D'Souza; Peter Gilbert; Beatrice H Hahn; Nancy L Haigwood; Lynn Morris; Christos J Petropoulos; Victoria R Polonis; Marcella Sarzotti; David C Montefiori
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

2.  TLR2 signaling renders quiescent naive and memory CD4+ T cells more susceptible to productive infection with X4 and R5 HIV-type 1.

Authors:  Sandra Thibault; Mélanie R Tardif; Corinne Barat; Michel J Tremblay
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

3.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

4.  Expression and use of human immunodeficiency virus type 1 coreceptors by human alveolar macrophages.

Authors:  S Worgall; R Connor; R J Kaner; E Fenamore; K Sheridan; R Singh; R G Crystal
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

5.  Structures of human genes coding for cytokine LD78 and their expression.

Authors:  M Nakao; H Nomiyama; K Shimada
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

6.  Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration.

Authors:  Vidita Choudhry; Mei-Yun Zhang; Ilia Harris; Igor A Sidorov; Bang Vu; Antony S Dimitrov; Timothy Fouts; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2006-08-04       Impact factor: 3.575

7.  Cutting edge: Experimentally induced immune activation in natural hosts of simian immunodeficiency virus induces significant increases in viral replication and CD4+ T cell depletion.

Authors:  Ivona Pandrea; Thaidra Gaufin; Jason M Brenchley; Rajeev Gautam; Christopher Monjure; Aarti Gautam; Clint Coleman; Andrew A Lackner; Ruy M Ribeiro; Daniel C Douek; Cristian Apetrei
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

8.  Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene.

Authors:  A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler
Journal:  Science       Date:  1998-12-11       Impact factor: 47.728

9.  HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes.

Authors:  Kosuke Miyauchi; Yuri Kim; Olga Latinovic; Vladimir Morozov; Gregory B Melikyan
Journal:  Cell       Date:  2009-05-01       Impact factor: 41.582

10.  Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.

Authors:  Jesus F Salazar-Gonzalez; Maria G Salazar; Brandon F Keele; Gerald H Learn; Elena E Giorgi; Hui Li; Julie M Decker; Shuyi Wang; Joshua Baalwa; Matthias H Kraus; Nicholas F Parrish; Katharina S Shaw; M Brad Guffey; Katharine J Bar; Katie L Davis; Christina Ochsenbauer-Jambor; John C Kappes; Michael S Saag; Myron S Cohen; Joseph Mulenga; Cynthia A Derdeyn; Susan Allen; Eric Hunter; Martin Markowitz; Peter Hraber; Alan S Perelson; Tanmoy Bhattacharya; Barton F Haynes; Bette T Korber; Beatrice H Hahn; George M Shaw
Journal:  J Exp Med       Date:  2009-06-01       Impact factor: 14.307

View more
  19 in total

1.  Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells.

Authors:  Christopher A Todd; Kelli M Greene; Xuesong Yu; Daniel A Ozaki; Hongmei Gao; Yunda Huang; Maggie Wang; Gary Li; Ronald Brown; Blake Wood; M Patricia D'Souza; Peter Gilbert; David C Montefiori; Marcella Sarzotti-Kelsoe
Journal:  J Immunol Methods       Date:  2011-09-22       Impact factor: 2.303

2.  Immunization with hybrid proteins containing the membrane proximal external region of HIV-1.

Authors:  Nicola Strasz; Vladimir A Morozov; Jürgen Kreutzberger; Martina Keller; Magdalena Eschricht; Joachim Denner
Journal:  AIDS Res Hum Retroviruses       Date:  2014-02-07       Impact factor: 2.205

3.  Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis.

Authors:  Nagadenahalli B Siddappa; Girish Hemashettar; Yin Ling Wong; Samir Lakhashe; Robert A Rasmussen; Jennifer D Watkins; Francis J Novembre; François Villinger; James G Else; David C Montefiori; Ruth M Ruprecht
Journal:  J Med Primatol       Date:  2010-11-02       Impact factor: 0.667

4.  Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies.

Authors:  Zhongyu Zhu; Haiyan Rebekah Qin; Weizao Chen; Qi Zhao; Xiaoying Shen; Robert Schutte; Yanping Wang; Gilad Ofek; Emily Streaker; Ponraj Prabakaran; Genevieve G Fouda; Hua-Xin Liao; John Owens; Mark Louder; Yongping Yang; Kristina-Ana Klaric; M Anthony Moody; John R Mascola; Jamie K Scott; Peter D Kwong; David Montefiori; Barton F Haynes; Georgia D Tomaras; Dimiter S Dimitrov
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

5.  Purification and functional characterization of mucosal IgA from vaccinated and SIV-infected rhesus macaques.

Authors:  Thomas Musich; Thorsten Demberg; Ian L Morgan; Jacob D Estes; Genoveffa Franchini; Marjorie Robert-Guroff
Journal:  Clin Immunol       Date:  2015-04-01       Impact factor: 3.969

6.  Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1.

Authors:  Andrew Rosa Borges; Lindsay Wieczorek; Benitra Johnson; Alan J Benesi; Bruce K Brown; Richard D Kensinger; Fred C Krebs; Brian Wigdahl; Robert Blumenthal; Anu Puri; Francine E McCutchan; Deborah L Birx; Victoria R Polonis; Cara-Lynne Schengrund
Journal:  Virology       Date:  2010-09-28       Impact factor: 3.616

Review 7.  Back to the future: covalent epitope-based HIV vaccine development.

Authors:  Sudhir Paul; Stephanie Planque; Yasuhiro Nishiyama; Miguel Escobar; Carl Hanson
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

8.  GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates.

Authors:  Emma L Mohr; Jinhua Xiang; James H McLinden; Thomas M Kaufman; Qing Chang; David C Montefiori; Donna Klinzman; Jack T Stapleton
Journal:  J Immunol       Date:  2010-09-08       Impact factor: 5.422

9.  Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.

Authors:  Marcella Sarzotti-Kelsoe; Robert T Bailer; Ellen Turk; Chen-li Lin; Miroslawa Bilska; Kelli M Greene; Hongmei Gao; Christopher A Todd; Daniel A Ozaki; Michael S Seaman; John R Mascola; David C Montefiori
Journal:  J Immunol Methods       Date:  2013-12-01       Impact factor: 2.303

10.  Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine.

Authors:  Stephanie A Planque; Yukie Mitsuda; Yasuhiro Nishiyama; Sangeeta Karle; Stephane Boivin; Maria Salas; Mary-Kate Morris; Mariko Hara; Guangling Liao; Richard J Massey; Carl V Hanson; Sudhir Paul
Journal:  J Immunol       Date:  2012-10-22       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.